Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rakesh Patel

Radiation Oncology Los Gatos, CA Medical Doctor

NPI 1992768519 CMS profile 181047

15400 National Ave, Suite 100, Los Gatos, CA 95032

Open in the dashboard

General payments

$1,347,225

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$1,241,728

6 holdings reported · through program year 2025

Through program year 2025, Rakesh Patel of Los Gatos, CA is reported in the CMS Open Payments database as having received $1,347,225 across 71 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,241,728 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $270 3
2024 General $123,398 10
2023 General $89,337 5
2022 General $270,137 7
2021 General $561,057 6
2020 General $230,684 15
2019 General $72,343 25
2024 Ownership $189,548 1
2023 Ownership $113,857 1
2022 Ownership $113,857 1
2021 Ownership $62,217 1
2020 Ownership $123,791 1
2019 Ownership $638,457 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rakesh Patel
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Rakesh Patel were reported at $270. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Rakesh Patel Radiation Oncology median Middle half National median
2019 $72,343 $138 $48–$462 $163
2020 $230,684 $79 $26–$262 $114
2021 $561,057 $119 $37–$358 $132
2022 $270,137 $139 $43–$424 $149
2023 $89,337 $167 $57–$473 $160
2024 $123,398 $168 $56–$541 $164
2025 $270 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. iCAD, Inc $1,305,922 24 payments
  2. Bioptics, Inc. $20,000 1 payment
  3. Varian Medical Systems, Inc. $18,936 8 payments
  4. Hologic Inc $750 1 payment
  5. Endomagnetics Ltd $450 2 payments
  6. Siemens Medical Solutions USA, Inc. $367 3 payments
  7. Volpara Solutions Inc $137 1 payment
  8. Myriad Genetic Laboratories, Inc. $137 6 payments
  9. AstraZeneca Pharmaceuticals LP $113 6 payments
  10. Pfizer Inc. $101 5 payments
  11. Other $312 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $756,000 2 payments
  2. Consulting Fee $298,755 16 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $269,998 11 payments
  4. Grant $20,000 1 payment
  5. Food and Beverage $1,875 39 payments
  6. Travel and Lodging $597 2 payments
Products named General payments · program years 2019–2025
  1. OTHER $16,735 6 payments
  2. Radiation Oncology $2,201 2 payments
  3. Magseed $450 2 payments
  4. Varian Ethos Treatment Planning $179 1 payment
  5. Magtrace $156 1 payment
  6. myRisk $137 6 payments
  7. AXXENT SURFACE CONTROLLER $137 1 payment
  8. TAGRISSO $71 4 payments
  9. IBRANCE $62 3 payments
  10. Nplate $44 2 payments
  11. Other $601 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$58,262

Medicare's payments for the services billed

Medicare patients

50

Average age 77

Services billed

905

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 72%
Arthritis 46%
Diabetes 28%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record